Axonics, Inc. (AXNX)
NASDAQ: AXNX · IEX Real-Time Price · USD
66.57
-0.36 (-0.54%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Axonics Revenue
In the year 2023, Axonics had annual revenue of $366.38M with 33.86% growth. Revenue in the quarter ending December 31, 2023 was $109.74M with 27.72% year-over-year growth.
Revenue (ttm)
$366.38M
Revenue Growth
+33.86%
P/S Ratio
9.27
Revenue / Employee
$459,698
Employees
797
Market Cap
3.40B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 366.38M | 92.68M | 33.86% |
Dec 31, 2022 | 273.70M | 93.41M | 51.81% |
Dec 31, 2021 | 180.29M | 68.76M | 61.64% |
Dec 31, 2020 | 111.54M | 97.72M | 707.05% |
Dec 31, 2019 | 13.82M | 13.11M | 1,854.74% |
Dec 31, 2018 | 707.00K | 579.00K | 452.34% |
Dec 31, 2017 | 128.00K | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 5.86B |
Fortrea Holdings | 3.11B |
Envista Holdings | 2.57B |
HUTCHMED (China) | 838.00M |
10x Genomics | 618.73M |
iRhythm Technologies | 492.68M |
Axsome Therapeutics | 270.60M |
SpringWorks Therapeutics | 5.45M |
AXNX News
- 9 hours ago - Axonics Reports First Quarter 2024 Financial Results - Business Wire
- 6 days ago - Boston Scientific Announces Results for First Quarter 2024 - PRNewsWire
- 26 days ago - FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal - Reuters
- 5 weeks ago - Axonics Stockholders Approve Merger Agreement with Boston Scientific - Business Wire
- 5 weeks ago - Axonics Provides Update on Inter Partes Review Proceedings - Business Wire
- 6 weeks ago - Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System - Business Wire
- 2 months ago - Axonics Responds to ITC Action by Medtronic - Business Wire
- 2 months ago - Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results - Business Wire